ARG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Since nor−NOHA is effective in targeting ARG2-expressing leukemia cells, we wondered if nor−NOHA could attenuate hypoxia−mediated imatinib resistance in CML cells.